# Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

> **NCT00373516** · PHASE2 · COMPLETED · sponsor: **QuatRx Pharmaceuticals Company** · enrollment: 150 (—)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Vehicle (Placebo) applied BID
- **DRUG:** QRX-101 75 mcg/g ointment applied QD
- **DRUG:** QRX-101 75 mcg/g ointment applied BID

## Key facts

- **NCT ID:** NCT00373516
- **Lead sponsor:** QuatRx Pharmaceuticals Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 150 (—)
- **Last updated:** 2006-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373516, "Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00373516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*